Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 91 - 100 of 120

Selected Filters:
14 October 2022

Long-acting injectable cabotegravir for HIV prevention: WHO guidelines, implementation considerations, and project examples

Recording During this 90-minute webinar, speakers will provide an overview of the new WHO guidelines on CAB for PrEP, discuss implementation issues specifically relating to HIV testing and drug resistance, and highlight examples of planned implementation projects in sub-Saharan Africa and Asia. This webinar is presented by the Global PrEP Network, a WHO-led forum designed…

Research, Normative Guidance/Policies, Testing

Event
4 October 2022

Acceptability of Injectable Pre-exposure Prophylaxis among People who Inject Drugs in Three Urban U.S. Settings

This article from BMC Infectious Diseases examines acceptability of injectable PrEP amongst people who inject drugs in the US.

Research

External Link
4 October 2022

Long-Acting Injectable Cabotegravir for HIV Prevention: What do we know and need to know about the risks and consequences of cabotegravir resistance?

This article from The Science of Prevention summarizes what is known about cabotegravir (CAB) pharmacokinetics, activity, and emergence of resistance from in vitro, macaque and clinical studies, and evaluates the risk of resistance from CAB for PrEP with on-time injections and after CAB for PrEP discontinuation.

Monitoring & Evaluation, Research, Testing

External Link
31 August 2022

Coordinating Implementation Science for CAB for PrEP: Focus on Delivery Models

This second meeting of the BioPIC implementation science series focused on how cabotegravir (CAB) for PrEP can be integrated into existing community, pharmacy and facility-based delivery for HIV prevention.

Research

Document
19 August 2022

Implementation Science Questions for CAB for PrEP

This document outlines the key evidence gaps around cabotegravir (CAB) for PrEP that should be addressed when designing implementation research.

Research

Document
16 August 2022

Background Resources on Cabotegravir for PrEP

This document, produced by the MOSAIC consortium, provides a list of key resources on research and evidence for cabotegravir (CAB) for PrEP.

Research

Document
12 August 2022

A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP

AVAC’s Plan for Accelerating Access and Introduction of Injectable Cabotegravir (CAB) for PrEP provides a comprehensive view of all the moving parts involved in delivering this new PrEP option and identifies priorities for ensuring time is not wasted and opportunity is not squandered. The plan focuses on learning the lessons from the first ten years…

Community/Advocacy

External Link
8 August 2022

Long-Acting Injectable Cabotegravir: Implementation science needed to advance this additional HIV prevention choice

In this article, the authors outline priority areas for implementation research needed to inform the effective scale-up of cabotegravir for PrEP.

Research

External Link
8 August 2022

Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women

This press release provides an overview of the new findings from HPTN 084, a trial of the HIV Prevention Trials Network studying injectable cabotegravir for PrEP among cisgender women. The updated results show reductions in HIV incidence were sustained in the 12 months following unblinding and were presented at the AIDS 2022 conference in Montreal.

Research

External Link
5 August 2022

WHO Guidelines on Long-Acting Injectable Cabotegravir for HIV Prevention

WHO guidelines, issued in 2022, recommend injectable cabotegravir (CAB) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. These guidelines provide considerations to support managers, policy makers, researchers, health workers, communities, and other stakeholders in the implementation of projects and programs for injectable CAB for PrEP. It…

Normative Guidance/Policies

Document